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Genomic insights into adverse drug reactions
Carbamazepine  (CBZ)  is  a  drug  frequently  used  as  an 
anticonvulsant and mood stabilizer in the treatment of 
epilepsy  and  bipolar  disorder.  Cutaneous  adverse  drug 
reactions (cADRs) characterized by acute inflammatory 
reactions  in  skin  and  mucous  membranes  are  dose-
independent, unpredictable and sometimes life-threatening. 
Manifestations  range  from  a  mild  erythematous 
maculopapular rash to a progressive, fulminating, severe 
variant with extensive mucocutaneous epithelial necrosis, 
Stevens-Johnson  syndrome  (SJS),  toxic  epidermal 
necrolysis  (TEN)  and  drug-induced  hypersensitivity 
syndrome (DIHS), which is also referred to as drug rash 
with  eosinophilia  and  systemic  symptoms  (DRESS). 
Almost all available drugs have been reported to have a 
risk of causing a cADR, and some drugs, such as CBZ, 
allopurinol, abacavir and nevirapine, are known to cause 
a very high incidence of severe cADRs, including SJS and 
TEN [1].
It  has  been  proposed  recently  that  binding  of  drugs 
and/or  their  metabolites  to  human  leukocyte  antigen 
(HLA) may trigger undesirable immune responses. When 
the antigen is presented on HLA class II molecules, CD4+ 
helper T cells are activated. If the antigen is presented on 
class I molecules, it is likely to activate CD8+ cytotoxic T 
cells. Although the detailed mechanisms have not been 
clarified, HLA molecules are considered to be critical in 
the  pathogenesis  of  severe  cADRs.  Therefore,  genetic 
association  analyses  between  HLA  alleles  and  cADRs 
have  been  performed  by  many  research  groups,  and 
several  HLA  alleles  have  been  identified  as  major 
susceptibility  factors  that  predispose  an  individual  to 
develop  cADRs.  The  first  report  demonstrating  the 
critical  involvement  of  a  specific  HLA  allele  in 
development of severe cADRs was published in 2002 [2]. 
This  discovery  had  a  big  impact  and  resulted  in 
alterations to the labeling of drugs. The report described 
a  study  of  18  Caucasian  HIV  patients  with  abacavir-
induced hypersensitivity syndrome (HSS), and it revealed 
that the frequency of HLA-B*5701 in these patients was 
significantly higher compared with the abacavir-tolerant 
control subjects (78% versus 2%; odds ratio, 117). Based 
on the subsequent large prospective clinical trial in 2008 
[3],  the  US  Food  and  Drug  Administration  (FDA) 
updated  the  label  of  abacavir  to  recommend  that  all 
patients  should  be  screened  for  HLA-B*5701  before 
initiation of treatment.
New insights into carbamazepine reactions and 
HLA
Two  studies  published  recently  in  the  New  England 
Journal of Medicine should facilitate the development of 
genetic  tests  to  predict  high-risk  individuals  for 
potentially life-threatening adverse reactions caused by 
CBZ [4,5]. Previously, a group in Taiwan reported that 
the  HLA-B*1502  allele  was  associated  with  SJS-TEN 
induced by CBZ in Han Chinese patients (Table 1) [6,7]. 
Based  on  these  results,  in  2007  the  US  FDA 
recommended  genotyping  all  patients  with  ancestry  in 
populations in which HLA-B*1502 may be present. The 
recent  prospective  clinical  trial,  published  in  the  New 
England Journal of Medicine, led by the same Taiwanese 
group,  demonstrated  that  SJS-TEN  did  not  develop  in 
any of the HLA-B*1502-negative patients receiving CBZ 
(n  =  4,120),  indicating  that  the  HLA-B*1502  screening 
should reduce the incidence of life-threatening adverse 
reactions caused by CBZ [4]. However, allelic frequencies 
of the HLA loci differ significantly among different ethnic 
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© 2011 BioMed Central Ltdgroups. For example, the HLA-B*1502 allele is present at 
high frequencies in Southeast Asians, such as the Han 
Chinese  in  Taiwan  (5.9%)  and  people  from  Thailand 
(8.5%), but it is less than 0.1% in Japanese and Caucasian 
populations [8], although the incidence of CBZ-induced 
cADRs is also relatively high in these populations. Thus, 
HLA-B*1502 is unlikely to be a good genetic predictor for 
the  CBZ-induced  cADRs  in  Japanese  and  Caucasian 
populations.
The second study was a multicenter study led by teams 
from  the  UK  and  Ireland,  and  it  used  a  genome-wide 
association study (GWAS) approach. The study showed 
that  the  HLA-A*3101  allele  was  associated  with  CBZ-
induced cADRs, including SJS-TEN [5]. It demonstrated 
that  a  SNP  showing  a  significant  association  had 
previously been shown to be a proxy for the HLA-A*3101 
allele in subjects of European descent. The subsequent 
HLA analysis revealed that HLA-A*3101 was a risk factor 
for  the  HSS  (odds  ratio,  12.41),  maculopapular 
exanthema (MPE; odds ratio, 8.33) and SJS-TEN (odds 
ratio, 25.93), suggesting that the HLA-A*3101 allele is an 
important  predictor  of  the  ‘full  spectrum’  of  CBZ-
induced cADRs (Table 1). The authors concluded that it 
may be possible to reduce the incidence of CBZ-induced 
cADRs  from  5%  to  3.8%  by  using  genetic  diagnosis  to 
exclude patients with the HLA-A*3101 allele from CBZ 
treatment.
Implications for future research and treatment
Previously,  and  also  using  a  GWAS,  we  reported  that 
HLA-A*3101 allele was a genetic risk factor for the full 
spectrum  of  CBZ-induced  cADRs,  including  SJS-TEN 
and DIHS/DRESS, in a Japanese population (Table 1) [9]. 
In addition, this allele has been shown to be associated 
with  CBZ-induced  MPE  in  subjects  of  Han  Chinese 
ancestry (Table 1) [7]. HLA-A belongs to the HLA class I 
heavy  chain  paralogs  that  play  a  central  role  in  the 
immune system by presenting peptides derived from the 
endoplasmic reticulum lumen. It is considered that the 
association of the HLA allele with CBZ-induced cADRs 
should reflect variations in antigen-binding affinities of 
HLA-A  that  might  affect  the  immune  response  in  the 
pathogenesis of the cADRs. Patients will greatly benefit 
from HLA-A*3101 genotyping to predict the risk of CBZ-
induced  cADRs  because  there  are  several  alternative 
drugs  to  CBZ  for  treatment  of  epilepsy;  these  drugs 
include  valproic  acid,  gabapentin,  levetiracetam,  and 
topiramate, which induce cADRs with lower prevalence 
compared  with  CBZ.  Although  the  efficacy  of  these 
alternative drugs might be inferior to CBZ for treating 
epilepsy, the prevention of CBZ-induced cADRs, which 
are  sometimes  life-threatening,  is  more  important  for 
patients.  Thus,  these  findings  should  provide  useful 
information  for  improving  the  personalized  CBZ 
treatment of epilepsy.
Interestingly, the Taiwanese study revealed that MPE 
and  HSS  did  not  show  a  significant  association  with 
HLA-B*1502 (with only one positive subject out of thirty-
one patients), while the HLA-A*3101 allele was observed 
in only one of sixty patients with SJS-TEN [7], suggesting 
that  the  pathogenesis  might  be  different  between  SJS-
TEN and other cADRs, such as MPE. However, the full 
spectrum  of  CBZ-induced  cADRs,  including  SJS-TEN, 
was associated with the HLA-A*3101 allele in Japanese 
Table 1. HLA alleles associated with carbamazepine-induced cutaneous adverse drug reactions
Population	 Target	allele	 Type	of	cADR	 Selectivity	in	casesa	 Odds	ratio	 Reference
Han Chinese in Taiwan  HLA-B*1502	 SJS-TEN  59/60  1,357  [7]
  	 HSS  0/13  –  [7]
  	 MPE  1/18  –  [7]
  HLA-A*3101	 SJS-TEN  1/60  –  [7]
  	 HSS  2/13  –  [7]
  	 MPE  6/18  17.5  [7]
Japanese  HLA-A*3101	 SJS-TEN  5/6  33.9  [9]
    DIHS  21/36    9.5  [9]
    Other  19/35    8.0  [9]
European  HLA-A*3101	 SJS-TEN  5/12  25.93  [5]
    HSS  10/27  12.41  [5]
    MPE  23/106    8.33  [5]
Thai  HLA-B*1502	 SJS-TEN  37/42  54.76  [10]
Malaysian  HLA-B*1502	 SJS-TEN  12/16  16.15  [11]
aNumber of patients with the target allele/number of patients with type of cADR. cADR, cutaneous adverse drug reaction; DIHS, drug-induced hypersensitivity 
syndrome; HLA, human leukocyte antigen; HSS, hypersensitivity syndrome; MPE, maculopapular exanthema; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal 
necrolysis.
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belong  to  major  histocompatibility  complex  class  I 
molecules.  Thus,  there  may  be  common  underlying 
mechanisms  involved  in  the  CBZ-induced  cADRs, 
although HLA-B*1502 appears to be specifically involved 
in CBZ-induced SJS-TEN. The discrepancy in the results 
of  association  of  HLA-A*3101  with  SJS-TEN  between 
Japanese/European and Taiwanese studies might be due 
to ethnic differences in allele frequencies of HLA-B*1502. 
It has been found that the HLA-B*1502 allele is extremely 
rare in Japanese and Caucasians, and this might have a 
larger  effect  size  on  the  risk  of  SJS-TEN  than  that  of 
HLA-A*3101.
Although the impact of the association of HLA-A*3101 
with CBZ-induced cADRs is not as high as that of HLA-
B*1502,  improved  labeling  of  CBZ  to  recommend  the 
avoidance of CBZ in patients with HLA-A*3101 should 
benefit individuals at risk. However, a global network for 
the collection of data on patients with cADRs is required 
to  show  the  usefulness  of  HLA  testing  for  epilepsy 
treatments. In addition, the clarification of the molecular 
mechanisms underlying the associations of HLA-B*1502 
and HLA-A*3101 with the risk of CBZ-induced cADRs 
would  encourage  the  development  of  new  technology, 
which may also be useful for the screening of compounds 
for toxicity earlier in the drug discovery process.
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